IBT fortsätter rekrytera för tidigt födda barn till The Connection Study efter planerad säkerhetsanalys
21 juin 2023 02h55 HE
|
Infant Bacterial Therapeutics AB
I enlighet med studieprotokollet har den oberoende Data Monitoring Committee (DMC) utfört den sista planerade säkerhetsanalysen av Infant Bacterial Therapeutics AB (IBT) läkemedelskandidat IBP-9414....
IBT continues to recruit prematurely born infants to The Connection Study following a planned safety analysis.
21 juin 2023 02h55 HE
|
Infant Bacterial Therapeutics AB
In accordance with the study protocol, the independent Data Monitoring Committee (DMC) has performed the final planned safety analysis of Infant Bacterial Therapeutics AB (IBT) drug candidate...
Nytt patent för Infant Bacterial Therapeutics godkänt i Europa
15 juin 2023 09h45 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) meddelar idag att Europeiska patentverket godkänt bolagets patentansökning för Lactobacillus reuteri. Patentet gäller läkemedelskandidaten IBP-9414, som för...
New patent for Infant Bacterial Therapeutics has been approved in Europe
15 juin 2023 09h45 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) announces today that the European Patent Office has approved its patent application for Lactobacillus reuteri. The patent pertains to the drug candidate...
IBT offentliggör prospekt
13 juin 2023 05h15 HE
|
Infant Bacterial Therapeutics AB
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SCHWEIZ, SINGAPORE, SYDAFRIKA,...
IBT publishes prospectus
13 juin 2023 05h15 HE
|
Infant Bacterial Therapeutics AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND,...
Extra bolagsstämma i Infant Bacterial Therapeutics
09 juin 2023 05h04 HE
|
Infant Bacterial Therapeutics AB
På extra bolagsstämman i Infant Bacterial Therapeutics AB (publ) den 9 juni 2023 beslutades att godkänna styrelsens beslut från den 16 maj 2023 om att bolagets aktiekapital ska ökas genom emission av...
Extraordinary General Meeting of Infant Bacterial Therapeutics
09 juin 2023 05h04 HE
|
Infant Bacterial Therapeutics AB
At the Extraordinary General Meeting of Infant Bacterial Therapeutics AB (publ) on June 9, 2023, it was resolved to approve the Board of Directors’ resolution from May 16, 2023 to increase the...
Digital Twin Consortium Welcomes NEC as Member
24 mai 2023 09h00 HE
|
Digital Twin Consortium
BOSTON, MA, May 24, 2023 (GLOBE NEWSWIRE) -- The Digital Twin Consortium® (DTC) today announced that NEC Corporation (NEC; TSE: 6701), a leader in the integration of IT and network technologies, has...
Notice of Extraordinary General Meeting of Infant Bacterial Therapeutics
16 mai 2023 17h31 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Extraordinary General Meeting to be held on Friday June 9, 2023 at 10.00...